All Eyes on Valeant Pharma (VRX) EBITDA, Which is Expected to be Lowered - Evecore ISI's Raffat
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Valeant Pharma (NYSE: VRX) analyst Umer Raffat from Evecore ISI weighed in ahead of tomorrow's all-important second quarter report. He said by and far the key will be EBITDA.
He notes current 2016 EBTIDA guidance is $4.8 - $4.95B. Further he notes that ~75% investors in his recent buyside survey expected Valeant to lower 2016 EBITDA.
For Q2 EBITDA, the consensus is ~$1.1B.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Community Health (CYH) to Underperform
- Jefferies Raises Price Target on Coca Cola (KO) to $46 Following 3Q; Reaffirmed Guidance
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Hot Comments, Trader Talk
Related EntitiesUmer Raffat
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!